Immunereaction | Reference | Year | Humoral resp. Ig/A/G/M | Cellular assays |
---|---|---|---|---|
Anti-69 kD protein | 62 | 1991 | Ig | |
Anti-anter.longit.ligament | 90 | 1983 | Stim. | |
Anti-articular cart(ilage) | 91 | 1976 | Ig | MI |
Anti-C1q | 92 | 1992 | G, A | |
Anti-cardiolipin | 63 | 1987 | G+M | |
64 | 1989 | Ig | ||
57 | 1995 | G,M,A >16 units | ||
Anti-cart.link protein | 93 | 1988 | Ig | |
Anti-collagen n1;n2;n3;α | 94 | 1980 | Stim. | |
d1 | 95 | 1980 | Stim. | |
n1;n2 | 96 | 1980 | G | |
n2 | 97 | 1981 | G, M | |
d2;n2 | 98 | 1984 | G | |
C2 peptides | 99 | 1994 | CTL cloning | |
n2 | 61 | 1997 | G,A,M | |
n | 60 | 1997 | A | |
Anti-DNA ss; ds | 63 | 1987 | G, M | |
69 | 1992 | Ig >1:10 | ||
Anti-HSP60 | 56 | 1996 | G Mean Abs. | |
Anti-intervertebral disc | 90 | 1983 | Stim. | |
Anti-keratin | 100 | 1994 | A,G,M Mean Abs | |
ANCA | 101 | 1995 | G, A | |
ANF Liver | 65 | 1967 | Ig ⩾1:16 | |
Liver | 66 | 1967 | Ig | |
Liver | 67 | 1967 | Ig ⩾1:16 | |
Leucocytes | 58 | 1977 | Ig | |
Granulocytes; liver | 68 | 1979 | Ig 1:40 | |
Leucocytes | 59 | 1981 | Ig 1:20 | |
69 | 1992 | Ig >1:40 | ||
Hep-2 | 101 | 1995 | G | |
102 | 1993 | |||
APF | 103 | 1995 | Ig 1:80 1:100 | |
104 | 1979 | Ig 1:80 | ||
105 | 1990 | Ig 1:80 | ||
Anti-sacroileac joint cart. | 90 | 1983 | Stim. | |
Anti-salivaryduct | 106 | 1967 | Ig | |
Anti-synovial membrane | 91 | 1976 | Ig | MI |
Anti-thyroglobulin | 107 | 1979 | Ig | |
Immunereaction | Reference | Osteoarthritis | Degenerative joint disease | Gout |
Anti-69 kD protein | 62 | |||
Anti-anter.longit.ligament | 90 | |||
Anti-articular cart(ilage) | 91 | |||
Anti-C1q | 92 | |||
Anti-cardiolipin | 63 | |||
64 | ||||
57 | ||||
Anti-cart.link protein | 93 | 7/29 | ||
Anti-collagen n1;n2;n3;α | 94 | 0;0;0;3/10 | 0;2;1;3/10 | |
d1 | 95 | 3/15 | ||
n1;n2 | 96 | |||
n2 | 97 | |||
d2;n2 | 98 | |||
C2 peptides | 99 | |||
n2 | 61 | |||
n | 60 | |||
Anti-DNA ss; ds | 63 | |||
69 | ||||
Anti-HSP60 | 56 | |||
Anti-intervertabral disc | 90 | |||
Anti-keratin | 100 | |||
ANCA | 101 | |||
ANA Liver | 65 | 0/8 | ||
Liver | 66 | 0/15 | 0/13 | |
Liver | 67 | |||
Leucocytes | 58 | |||
Granulocytes/liver | 68 | |||
Leucocytes | 59 | |||
69 | ||||
Hep-2 | 101 | |||
102 | ||||
APF | 103 | |||
104 | 2/32 | |||
105 | ||||
Anti-sacroileac joint cart. | 90 | |||
Anti-salivaryduct | 106 | 0/43 | 0/6 | |
Anti-synovial membrane | 91 | |||
Anti-thyroglobulin | 107 | 1/2 SF |
Ankylosing spondylitis | Reactive arthritis | Reiter syndrome | SpA | RA |
---|---|---|---|---|
?/138 | ?/29 | |||
0/8 | ||||
Ig: 0/15 MI NS | Ig:0/25 MI>Contr. | |||
G:3/40 A:8/40 | G:4/80 A:1/80 | |||
2/28 | 3/10 | |||
0/41 | 14/110 | |||
G:24/84* M:7/84 A:0/84 | ||||
3/9 NS | 9/38 | |||
2;2;2;5/10 | 9;10;10;16/20 | |||
1/9 | 16/38 | |||
6;6/20 Mean: 0,87;0,95* | 23;20/471,1* ;1,3* | |||
G: 5/18 M: 1/18 | G:13/33 M: 18/33 | |||
1;¼ | 2,0/2 | 37;11/102 | ||
0/8 | 1/3 | |||
Mean: 0,11*0,07* 0,14 | m: 0,25* 0,06 0,15* | |||
Mean↑* | ||||
G: 5;0/28 M: 1;1/28 | G:1;0/10 M:2;2/10 | |||
0/3 | ||||
1.6* n=9 | 0,87 n=9 | |||
0/8 | ||||
9,15,13 n=20 NS | 8,19,13 n=11 NS | |||
G:12/22 A:8/22 | ||||
0/2 | 1/9 | 31/110 | ||
0/27 | 14/107 | |||
0/18 (AS+PsoA) | 59/184 | |||
75/125* | 58/124 * | |||
5/88; 6/36 | ||||
7/31* | ||||
0/3 | ||||
0/22 | ||||
7/84 | ||||
26/80 | 8/43 6/123 | |||
2/36 | 80/103 | |||
3/52 | 2/26 | 76/100 | ||
0/8 | ||||
0/1 | 2/9 | 34/129 | ||
Ig: 0/15MI>Contr.* | g:0/25 MI>Contr. | |||
1/1 SF | 5/41 SF | |||
SLE | Psoriatic arthritis | Normal controls | Sex/HLA matches | Conclusions |
?/38 | No | |||
n=8 | No | |||
0/25 | No | |||
G:30/88 A:0/88 | 3/80 2/80 | No | ||
0/10 | No | |||
36/117 | 2/19 | 0/152 | No | |
G:2/40 M:3/40 A:0/40 | Sex + age | + | ||
4/9 | 7/13 | 21/83 | No | |
0;0;0;1/10 | No | |||
3/17 | No | |||
0,0/14 | n=40 | No | ||
G: 0/14 M: 1/14 | n=15 | No | ||
2;0/8 | 2;1/50 | No | ||
0/4 | No | |||
m: 0,09 0,06 0,12 | No | + | ||
n=30 | No | + | ||
G:0;0/10 M:1;1/10 | No | |||
No | ||||
1,0 n=12 | 0,96 n=9 | No | + | |
n=8 | No | |||
24 *,11,12 n=42 | 9,13,16 n=58 | No | ||
No | ||||
0/6 | No | |||
0/7 | No | |||
55/55 | 0/18 PsoA+AS | 0/66 | No | |
11/122 | No | + | ||
7/52, 1/32 | No | |||
0/31 | Sex + age | + | ||
No | ||||
— | ||||
No | ||||
No | ||||
4/111 | No | |||
5/34 | 3/108 | No | ||
n=8 | No | |||
¼ | 0/9 | No | ||
0/25 | No | |||
No |
↑ = Increased mean absorbance in ELISA. Bold type* = significant (p<0.05) if compared with healthy controls. + = Significantly increased frequency of autoimmune reactions among B27 associated SpA compared with controls (healthy or suffering from other rheumatic disorders). A = IgA, Abs = absorbance in ELISA assay, Arthr = arthritis, Cart = cartilage, Deg = degenerative, ds = double stranded, G = IgG, Ig = immunoglobulin, m = mean, M = IgM, MI =migration inhibition, NS = not significant, resp = response, SLE = systemic lupus erythematosus, SF = synovial fluid, ss = single stranded, Stim = lymphocyte stimulation.